Wide Ranks

IMUX

Immunic, Inc.

1.20

Top Statistics
Market Cap 108 M Forward PE -1.58 Revenue Growth 0.00 %
Current Ratio 2.71 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.5220 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 59 M Total Cash Per Share 0.6560 Total Debt 899000
Total Debt To Equity 2.18 Current Ratio 2.71 Book Value Per Share 0.4580
All Measures
Short Ratio 296.00 % Message Board Id finmb_403013221 Shares Short Prior Month 3 M
Return On Equity -2.16 City New York Uuid 9418eda4-bdb2-33d3-9268-92e0d8463b7a
Previous Close 1.14 First Trade Date Epoch Utc 1 B Book Value 0.4580
Beta 1.88 Total Debt 899000 Volume 719647
Price To Book 2.62 Last Split Date 1 B Fifty Two Week Low 0.9700
Total Cash Per Share 0.6560 Shares Short Previous Month Date 1 B Target Median Price 10.50
Max Age 86400 Recommendation Mean 1.29 Sand P52 Week Change 0.3133
Target Mean Price 12.79 Net Income To Common -96904000 Short Percent Of Float 0.0425
Implied Shares Outstanding 90 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 781500 Average Volume10days 781500 Total Cash 59 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0344 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 1.14
Target Low Price 5.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.37
Open 1.16 Free Cashflow -45125248 State NY
Dividend Yield 0.00 % Return On Assets -0.9090 Time Zone Short Name EST
Trailing Eps -1.23 Day Low 1.15 Address1 1200 Avenue of the Americas
Shares Outstanding 90 M Price Hint 4 Target High Price 28.00
Website https://imux.com 52 Week Change 0.0084 Average Volume 815315
Forward Eps -0.6400 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 256.40 % Last Split Factor 1:40 Regular Market Day High 1.21
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 2.18
Fifty Two Week High 2.11 Day High 1.21 Shares Short 3 M
Regular Market Open 1.16 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0421 Operating Cashflow -75830000
Currency USD Time Zone Full Name America/New_York Market Cap 108 M
Is_nasdaq_100 False Zip 10036 Quote Type EQUITY
Industry Biotechnology Long Name Immunic, Inc. Regular Market Day Low 1.15
Held Percent Institutions 0.6502 Current Price 1.20 Address2 Suite 200
Enterprise To Ebitda -0.5220 Financial Currency USD Current Ratio 2.71
Industry Disp Biotechnology Number Of Analyst Opinions 7 Country United States
Float Shares 52 M Two Hundred Day Average 1.33 Enterprise Value 49 M
Forward PE -1.58 Regular Market Volume 719647 Ebitda -95680000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.

Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.

Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.